Editing Cancer vaccine (section)

== Approved oncovaccines ==
[[Oncophage]] was approved in Russia in 2008 for [[kidney cancer]]. It is marketed by Antigenics Inc.<ref>{{cite web |title=Recent Advances in Cancer Vaccines: An Overview Get access Arrow |url=https://academic.oup.com/jjco/article-abstract/39/2/73/806013?redirectedFrom=fulltext&login=false |access-date=24 December 2024}}</ref>

[[Sipuleucel-T]], [[Provenge]], was approved by the FDA in April 2010 for metastatic [[hormone-refractory prostate cancer]]. It is marketed by [[Dendreon]] Corp.

[[CimaVax-EGF]] was approved in Cuba in 2011.<ref>{{Cite web |last=Dillow |first=Clay |date=2011-09-08 |title=Cuba Announces Release of the World's First Lung Cancer Vaccine |url=https://www.popsci.com/science/article/2011-09/cuba-releases-worlds-first-lung-cancer-vaccine/ |access-date=2023-05-12 |website=Popular Science |language=en-US |archive-date=25 August 2017 |archive-url=https://web.archive.org/web/20170825024854/http://www.popsci.com/science/article/2011-09/cuba-releases-worlds-first-lung-cancer-vaccine |url-status=live }}</ref> Similar to Oncophage, it is not yet approved for use in the United States, although it is already undergoing phase II trials to that end.<ref>{{Cite web |title=Roswell Park Lung Cancer Expert Shares Initial Findings From First North American Study of CIMAvax |url=https://www.roswellpark.org/newsroom/201809-roswell-park-lung-cancer-expert-shares-initial-findings-first-north-american-study |access-date=2023-05-12 |website=Roswell Park Comprehensive Cancer Center |date=26 September 2018 |language=en |archive-date=12 May 2023 |archive-url=https://web.archive.org/web/20230512103345/https://www.roswellpark.org/newsroom/201809-roswell-park-lung-cancer-expert-shares-initial-findings-first-north-american-study |url-status=live }}</ref><ref>{{Cite web |title=With Safety Analysis Now Complete, Roswell Park Moves Forward With Expanded Study of CIMAvax |url=https://www.roswellpark.org/newsroom/201903-safety-analysis-now-complete-roswell-park-moves-forward-expanded-study-cimavax |access-date=2023-05-12 |website=Roswell Park Comprehensive Cancer Center |date=30 March 2019 |language=en |archive-date=12 May 2023 |archive-url=https://web.archive.org/web/20230512104846/https://www.roswellpark.org/newsroom/201903-safety-analysis-now-complete-roswell-park-moves-forward-expanded-study-cimavax |url-status=live }}</ref>

[[BCG vaccine|Bacillus Calmette-Guérin]] (BCG) was approved by the FDA in 1990 as a vaccine for early-stage bladder cancer.<ref>{{Cite web|url=https://www.cancerresearch.org/immunotherapy/cancer-types/bladder-cancer|title=Immunotherapy for Bladder Cancer|website=Cancer Research Institute|language=en|access-date=2019-10-13|archive-date=13 October 2019|archive-url=https://web.archive.org/web/20191013081509/https://www.cancerresearch.org/immunotherapy/cancer-types/bladder-cancer|url-status=live}}</ref> BCG can be administered intravesically (directly into the bladder) or as an [[adjuvant]] in other cancer vaccines.